Oramed Pharmaceuticals repurchases shares and ends joint venture with HTIT

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced this week that it has repurchased 1,155,367 shares of its common stock from Hefei Tianhui Biotech Co., Ltd. (HTIT Biotech) at $2.23 per share, totaling approximately $2.58 million. The transaction closed on Monday, and the repurchased shares have been cancelled and retired, according to a statement based on the company’s SEC filing.

In addition, Oramed terminated its joint venture agreement with HTIT Biotech and its subsidiary Technowl Limited. The original agreement, signed in January 2024, aimed to establish a joint venture focused on Oramed’s oral drug delivery technology. The parties had previously amended the agreement, setting an initial closing deadline of April 30, 2025, which was later extended. Oramed stated that HTIT was unable to satisfy the required closing conditions, leading to the termination notice issued on Thursday.

The company also issued a shareholder letter on Thursday containing certain unaudited, preliminary, and estimated financial information as of September 30, 2025. Oramed cautioned that this financial information is subject to adjustment and has not been audited.

Oramed’s common stock is listed on the Nasdaq Capital Market and the Tel Aviv Stock Exchange. This report is based on a press release statement and information disclosed in the company’s recent SEC filing.

In other recent news, Oramed Pharmaceuticals Inc. announced the initiation of a new trial for its oral insulin program following the termination of its joint venture with Hefei Tianhui Biotech Co. Ltd. The trial will focus on 60 U.S.-based participants identified as high responders, including those with lower BMI and older demographics, who showed potential for over a 1% reduction in HbA1c levels. Additionally, Oramed has completed the first tranche of a warrant repurchase agreement with Scilex Holding Company. Scilex repurchased warrants from Oramed to purchase 3,130,000 shares of common stock for $13 million, as part of an option agreement allowing for a total repurchase of 6,500,000 shares for $27 million. Furthermore, Oramed’s stockholders have approved an amendment to the company’s Amended and Restated 2019 Stock Incentive Plan during the 2025 Annual Meeting. This amendment increases the number of authorized shares for issuance by 2,000,000 to a total of 9,500,000 shares. The amendment also includes provisions for officers and directors to receive awards under the plan.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.